Department of Pharmacy, Hexi University Affiliated Zhangye People's Hospital, Zhangye, China.
Department of Endoscopy Center, Hexi University Affiliated Zhangye People's Hospital, Zhangye, China.
Cancer Control. 2023 Jan-Dec;30:10732748231197511. doi: 10.1177/10732748231197511.
We aimed to retrospectively investigate whether the neutrophil to lymphocyte ratio (NLR) and the monocyte to lymphocyte ratio (MLR) can predict the prognosis of patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib or sorafenib.
We retrospectively identified 210 patients with mRCC treated with sunitinib or sorafenib from 2007 to 2017 at Fudan University- and Hexi University-affiliated hospitals. Overall survival (OS) and progression-free survival (PFS) were evaluated using the Kaplan-Meier method. Multivariate regression analysis was used to evaluate predictors of PFS and OS.
Low NLR (<2.85) and MLR (<.30) were strongly associated with increased PFS and OS. Multivariable analyses verified that the NLR and MLR were both independent prognostic factors. Additionally, the NLR was negatively correlated with CD8 and CD4 T-cell infiltration in tumors.
In patients with mRCC treated with sunitinib and sorafenib, an NLR <2.85 and MLR <.30 was associated with superior PFS and OS, which may be related to the reduced lymphocytic infiltration of tumors.
我们旨在回顾性研究中性粒细胞与淋巴细胞比值（NLR）和单核细胞与淋巴细胞比值（MLR）是否可以预测接受舒尼替尼或索拉非尼治疗的转移性肾细胞癌（mRCC）患者的预后。
我们回顾性地确定了 2007 年至 2017 年在复旦大学和河西大学附属医院接受舒尼替尼或索拉非尼治疗的 210 例 mRCC 患者。使用 Kaplan-Meier 方法评估总生存期（OS）和无进展生存期（PFS）。多变量回归分析用于评估 PFS 和 OS 的预测因素。
低 NLR（<2.85）和 MLR（<.30）与延长 PFS 和 OS 密切相关。多变量分析证实，NLR 和 MLR 均为独立的预后因素。此外，NLR 与肿瘤中 CD8 和 CD4 T 细胞浸润呈负相关。
在接受舒尼替尼和索拉非尼治疗的 mRCC 患者中，NLR<2.85 和 MLR<.30 与更好的 PFS 和 OS 相关，这可能与肿瘤中淋巴细胞浸润减少有关。
